Key result
COX-2 selective inhibitors provide comparable efficacy to nonselective NSAIDs with fewer upper gastrointestinal events and no convincing evidence of increased cardiovascular risk at recommended doses.
Why the study?
Do COX-2 selective inhibitors increase the risk of cardiovascular thrombotic events compared to nonselective NSAIDs or placebo in patients with osteoarthritis and rheumatoid arthritis?
Do COX-2 selective inhibitors increase the risk of cardiovascular thrombotic events compared to nonselective NSAIDs or placebo in patients with osteoarthritis and rheumatoid arthritis?
COX-2 selective inhibitors at recommended doses do not increase cardiovascular risk compared to placebo or non-naproxen NSAIDs, and low-dose aspirin should be used for cardioprotection when appropriate.
No takes yet. Share an insight, caveat, or question.
Supports COX-2 selection for GI risk reduction in arthritis; leaves open confirmation of cardiovascular safety in large randomized trials.
Marc C. Hochberg (2003) conducted an editorial in Osteoarthritis and Rheumatoid Arthritis. COX-2 selective inhibitors vs. Nonselective NSAIDs was evaluated. COX-2 selective inhibitors provide comparable efficacy to nonselective NSAIDs with fewer upper gastrointestinal events and no convincing evidence of increased cardiovascular risk at recommended doses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: